A published real-world study (Advances in Therapy, 2025) documented mean weight loss of 14.1% for semaglutide and 16.5% for tirzepatide over one year in nearly 10,000 patients on FDA-approved formulations - these research figures are not specific to compounded programs or to WellMedr
BPC-157 peptide appears to bind with growth hormone receptors, possibly stimulating cell proliferation
Packaged in the USA by a family owned and operated company since 1968
Available from: 76
Tirzepatide is known for potential nausea, vomiting, diarrhea, or constipation, especially during dose escalation
Originally isolated from human gastric juice, this 15-amino acid compound has been studied in preclinical animal models across multiple physiological systems.*1,9,10